Raloxifene No Prescription
Raloxifene is prescribed for the prevention of osteoporosis in post-menopausal women.
Raloxifene is used to prevent and treat osteoporosis (condition in which the bones become thin and weak and break easily) in women who have undergone menopause (change of life; end of menstrual periods). Raloxifene is also used to decrease the risk of developing invasive breast cancer (breast cancer that has spread outside of the milk ducts or lobules into the surrounding breast tissue) in women who are at high risk of developing this type of cancer or who have osteoporosis. Raloxifene cannot be used to treat invasive breast cancer or to prevent invasive breast cancer from coming back in women who have already had the condition. Raloxifene also cannot be used to decrease the risk of developing non-invasive breast cancer. Raloxifene is in a class of prescriptions called selective estrogen receptor modulators (SERMs). Raloxifene prevents and treats osteoporosis by mimicking the effects of estrogen (a female hormone produced by the body) to increase the density (thickness) of bone. Raloxifene decreases the risk of developing invasive breast cancer by blocking the effects of estrogen on breast tissue. This may stop the development of tumors that need estrogen to grow.
A second generation selective estrogen receptor modulator (SERM) used to prevent osteoporosis in postmenopausal women. It has estrogen agonist effects on bone and cholesterol metabolism but behaves as a complete estrogen antagonist on mammary gland and uterine tissue.
Raloxifene is contraindicated in women who are or may become pregnant. Raloxifene may cause fetal harm when administered to a pregnant woman. In rabbit studies, abortion and a low rate of fetal heart anomalies (ventricular septal defects) occurred in rabbits at doses ? 0.1 mg/kg (? 0.04 times the human dose based on surface area, mg/m2), and hydrocephaly was observed in fetuses at doses ?10 mg/kg (? 4 times the human dose based on surface area, mg/m2). In rat studies, retardation of fetal development and developmental abnormalities (wavy ribs, kidney cavitation) occurred at doses ? 1mg/kg (?0.2 times the human dose based on surface area, mg/m2). Treatment of rats at doses of 0.1 to 10 mg/kg (0.02 to 1.6 times the human dose based on surface area, mg/m2) during gestation and lactation produced effects that included delayed and disrupted parturition; decreased neonatal survival and altered physical development; sex-and age-specific reductions in growth and changes in pituitary hormone content; and decreased lymphoid compartment size in offspring. At 10 mg/kg, raloxifene disrupted parturition which resulted in maternal and progeny death and morbidity. Effects in adult offspring (4 months of age) included uterine hypoplasia and reduced fertility; however, no ovarian or vaginal pathology was observed. The patient should be apprised of the potential hazard to the fetus if Raloxifene is prescribed during pregnancy, or if the patient becomes pregnant while taking Raloxifene.
Raloxifene is contraindicated in women with active or past history of venous thromboembolic events, including deep vein thrombosis, pulmonary embolism, and retinal vein thrombosis.
Raloxifene is contraindicated in women known to be hypersensitive to raloxifene or other constituents of the tablets.
Raloxifene Without a Prescription
Raloxifene comes as a tablet to take by mouth. It is usually taken once a day with or without food. Take raloxifene at around the same time every day.
Raloxifene, a selective estrogen receptor modulator (SERM) of the benzothiophene class, is similar to tamoxifen in that it produces estrogen-like effects on bone and lipid metabolism, while antagonizing the effects of estrogen on mammary tissue. Raloxifene decreases bone resorption, increases bone mineral density (BMD) and decreases incidence of fractures. Raloxifene is used in the prevention of postmenopausal osteoporosis and breast cancer.
Raloxifene Side Effects
Raloxifene side effects that you should report to your health care professional or doctor as soon as possible:
- difficulty falling asleep or staying asleep;
- flu-like syndrome;
- hot flashes (more common in the first 6 months of raloxifene therapy);
- joint pain;
- leg cramps;
- loss of coordination;
- swelling of the hands, feet, ankles, or lower legs;